United States Patent [19]

Keefer

[11] **Patent Number: 4,954,526**

[45] **Date of Patent: Sep. 4, 1990**

[54] **STABILIZED NITRIC OXIDE - PRIMARY AMINE COMPLEXES USEFUL AS CARDIOVASCULAR AGENTS**

[75] Inventor: **Larry K. Keefer**, Bethesda, Md.

[73] Assignee: **The United States of America as represented by the Department of Health and Human Services**, Washington, D.C.

[21] Appl. No.: **316,958**

[22] Filed: **Feb. 28, 1989**

[51] **Int. Cl.**[5] **A61K 31/13**; A61K 31/20; A61K 31/195; A61K 31/655

[52] **U.S. Cl.** **514/611**; 514/149; 514/558; 514/563; 514/564; 514/610; 564/112; 564/113

[58] **Field of Search** 514/645, 610, 615, 824, 514/611, 149, 558, 563, 564

[56] **References Cited**

U.S. PATENT DOCUMENTS

2,635,978	4/1953	Massengale	514/499
2,954,314	9/1960	Metzger	514/499
3,153,094	10/1984	Reilly	260/576
3,309,373	3/1967	Danzig	546/6
3,930,970	1/1976	Barton	260/397.5

FOREIGN PATENT DOCUMENTS

62-0175613 4/1987 Japan .

OTHER PUBLICATIONS

Drago & Karstetter, *The Reaction of NO with Various Primary & Secondary Amines*, Aug. 4, 1960, p. 1819, JACS.

Palmer et al., *Nitric Oxide Release Accounts for the Biological Activity of Endothelium-Derived Relaxing Factor*, Nature, pp. 524–526.

CA 108:68610c, *Red Blood Cells Generate Nitric Oxide from Directly Acting, Nitrogenous Vasodilators*, Kruzyna et al.

Palmer et al., Nature, 317, 524–526, 1987.

Kruszyna et al., Toxicol. and Applied Pharmacol., 91, 429–438, 1987.

Ignarro, The FASEB Journal, 3, 31–36, 1989.

Ignarro et al., J. Pharmacol. and Exper. Theraput., 218(2), 739–749, 1981.

Atston et al., The Journal of Biological Chemistry, 260(7), 4069–4074 and 9948, 1985.

Kubrina et al., Izvestiia Akademii Nauk SSSR.Seriia Biologicheska 6, 844–850, 1988 & Abstract.

Drago, "Free Radicals in Inorganic Chemistry", No. 36, Advances in Chemistry Series, American Chemical Society, Washington, DC, 1962, pp. 143–149.

Weirsdorff et al., Chemical Abstracts, 77: 48034f, 1972.

Fujitsuka et al., Chemical Abstracts, 82: 31108p, 1975.

DeLuca et al., Parenteral Drug Delivery Systems, pp. 238–250 of "Pharmaceutics and Pharmacy Practice", J. B. Lippincott Co., Philadelphia, 1987.

Toissel, ASHP, "Handbook on Injectable Drugs", 4th ed., pp. 622–630, 1986.

Primary Examiner—Allen J. Robinson

Attorney, Agent, or Firm—Birch, Stewart, Kolasch & Birch

[57] **ABSTRACT**

A method of treating cardiovascular disorders in a mammal, by administering to said mammal an effective amount of a compound of the formula:

$$[R—N(H)N(NO)O—]_yX$$

wherein R is loweralkyl, aryl, arylalkyl, or cycloalkyl, any of which R groups may be optionally substituted by one to three substituents selected from the group consisting of: halo, hydroxyl, alkoxy, amino, amido, formyl, carboxyl, or nitro; and wherein X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from loweralkyl, acyl or amido, and Y is 1 to 3 consistent with the valence of X. Pharmaceutical compositions containing the compounds are also provided.

20 Claims, No Drawings